<DOC>
	<DOCNO>NCT01371175</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability plasmid DNA recombinant MVA ( Modified Vaccinia Virus Ankara ) prime-boost regimen . Approximately 111 volunteer ( 90 vaccine recipients/21 placebo recipient ) enrol two site . Approximately 56 volunteer enrol site . An over-enrolment 10 % ( approximately 10 additional volunteer ) permit study .</brief_summary>
	<brief_title>A Phase IIA Trial Evaluate Safety Immunogenicity DNA HIV-1 Vaccine Followed MVA HIV-1 Vaccine HIV-uninfected Volunteers</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria 1 . Healthy male female ; 2 . Age least 18 year day screen great 60 year day enrolment ; 3 . Available follow plan duration study ( screen plus 18 month ) ; 4 . Able give write informed consent ; 5 . Does engage risk behaviour define protocol , willing undergo HIV test receive result ; 6 . If sexually active female , use effective method contraception ( combined oral contraceptive pill ; injectable contraceptive ; IUCD ; condom ; anatomical sterility self partner ) screen least 4 month last vaccination willing undergo urine pregnancy test screen prior vaccination 4 month last vaccination ; 7 . If sexually active male , willing use effective method contraception ( condom ) screen 4 month last vaccination . 1 . Clinically relevant abnormality history examination include history immunodeficiency use systemic corticosteroid , immunosuppressive , antiviral , anticancer , medication consider significant designated trial physician last 6 month ; 2 . Presence chronic condition ; 3 . Any following abnormal laboratory parameter moderate , severe , severe : haematology ( haemoglobin , absolute neutrophil count absolute lymphocyte count , absolute CD4 count , platelet ) ; urinalysis , biochemistry ( total bilirubin , creatinine , AST , ALT ) . Volunteers mild laboratory abnormality judge principal investigator designee clinically significant may enrol . 4 . If female , pregnant planning pregnancy within 4 month last vaccination lactating ; 5 . Receipt live attenuate vaccine within 60 day vaccine within 14 day enrolment ; 6 . Receipt blood transfusion blood product 6 month prior enrolment ; 7 . Participation another clinical trial investigational product currently within last 12 week expect participation study ; 8 . History severe local general reaction vaccination history allergic reaction ; 9 . History grandmal epilepsy , currently take antiepileptic ; 10 . Confirmed HIV1 HIV2 seropositive ; 11 . Positive hepatitis B ( surface antigen ) confirm diagnosis active syphilis time enrolment ( RPR positive TPHA positive equivalent ) , positive hepatitis C antibodies ; 12 . Unlikely comply protocol . Prior receipt smallpox vaccination document , exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>HIV</keyword>
</DOC>